D-Pharm Ltd., (TASE: DPRM) has received the first payment of $1M from Jiangsu NHWA Pharmaceutical Co., Ltd. (NHWA) in relation to DP-VPA development for epilepsy in China. NHWA is the leading Chinese company developing and marketing drugs to treat CNS disorders in China. DP-VPA is a novel drug discovered and...
Read more
Blog
cCam Raises $3 M
cCam Medical Ltd. has raised $3 million from Pontifax Ltd. and Mori Arkin’s Arkin Holdings Ltd. $2.5 million will be transferred at the signing and the balance in milestone payments. cCam also extended its cooperation agreement with Hoffmann-La Roche, which has the right to commercialize the company’s technology in exchange...
Read more
Pluristem Phase II Uses Placenta-Based Therapy
Pluristem Therapeutics, Inc. (NasdaqCM: PSTI; TASE: PLTR), has been granted clearance from the FDA to start a Phase II clinical trial using the company’s PLX-PAD cell product candidate for the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). Pluristem’s IC Phase II trial will evaluate the...
Read more
BioLert Links with My Epilepsy Diary
BioLert has linked the Epilert model V1 to the internet by developing software that interfaces with My Epilepsy Diary™, a service provided by the Epilepsy Therapy Project and Irody. http://www.epilepsy.com/epilepsy_therapy_project BioLert is the developer of the wearable Epilert Seizure Alert Device that automatically alerts families and caregivers of a patient...
Read more
Prolor: Positive Obesity/Diabetes Study
PROLOR Biotech, Inc. (NYSE Amex: PBTH) reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. The study was designed to measure the potential therapeutic effect of MOD-6030 injected once weekly as measured by weight loss, reduction in food intake, glycemic control and...
Read more